Cairo, 20 October 2026. Elixir Pharma has signed a strategic collaboration agreement with Audaxa Life Sciences, in cooperation with UK-based Beeko Solutions Ltd., to digitalize its pharmaceutical manufacturing and quality operations.
The agreement covers the implementation of an Electronic Quality Management System (eQMS), Electronic Batch Manufacturing Records (eBMR) and Product Quality Review (PQR) solutions. Together, they will strengthen quality processes, improve the traceability of manufacturing activities and batch records, and support the systematic review of production and quality data.

Dr. Hany Aly, Co-Founder and CEO of Elixir Pharma, said: “Pharmaceutical manufacturing carries a direct responsibility to patients. Every batch must be supported by controlled processes, reliable data and quality systems that enable consistency and accountability. Our investment in digitalization is about strengthening the infrastructure behind that responsibility, while developing the people and capabilities required to sustain high standards across our manufacturing operations.”
The systems will support the digital management of quality documentation and workflows, the recording of batch manufacturing activities and the review of product quality data. They will improve visibility across manufacturing processes, facilitate the documentation and
investigation of deviations, and support the management of corrective and preventive actions (CAPA).
By reducing reliance on paper-based records, electronic documentation will improve data accessibility, traceability and review efficiency, and will help align Elixir Pharma’s manufacturing operations with Good Manufacturing Practice (GMP) requirements and applicable regulatory standards.
Successful digitalization also depends on the people who operate and maintain these systems, so developing workforce capabilities will be an important part of integrating the solutions into routine manufacturing and quality operations.

Audaxa Life Sciences will work in cooperation with Beeko Solutions Ltd. to implement the specialized digital solutions, reflecting a shared focus on advancing quality management and operational capabilities through technology.
The agreement reflects Elixir Pharma’s commitment to strengthening the systems that underpin local pharmaceutical manufacturing, with a focus on process control, data integrity and the consistent application of quality standards in support of patients in Egypt.

Elixir is a young, innovative pharmaceutical company approaching its ninth year, building an integrated pharmaceutical platform in Egypt that brings together manufacturing, R&D, quality, technology, strategic partnerships, and the people who drive its progress. From its 22,000 m² GMP-compliant facility, with production capacity of up to 181,000 units, Elixir works with international partners to bring products, technologies, and expertise to Egypt, strengthen local pharmaceutical capabilities, and expand access to healthcare solutions. At the heart of this work are the patients who depend on the quality and reliability of its products, and the employees whose expertise, commitment, and continuous development make this responsibility possible.